Liver function may change how this drug works

NCT ID NCT05661344

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at how the drug BI 1015550 is absorbed and processed in the blood of people with mild or moderate liver problems compared to those with healthy livers. About 28 adults took a single dose and had blood samples taken over several days. The goal is to understand if liver impairment affects drug levels, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BI 1015550 (Nerandomilast)
What this could lead to: If successful, this study could help doctors determine the right dose of BI 1015550 for patients with liver problems, making the drug safer and more effective.
What could go wrong: This is a very early, small study (28 people) focused on drug levels, not on treating any disease. Results may not apply to all patients, and the drug could still cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hepatic Insufficiency liver disorder liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC INSUFFICIENCY

Contacts and locations

Locations

CRS Clinical Research Services Kiel GmbH

Kiel, 24105, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.